Thomas Breuer and colleagues at GlaxoSmithKline respond to Peter Doshi

摘要

We are writing to respond to The BMJ's feature article aboutthe Pandemrixvaccine (Feature, p 12). Our response focuses on some of the statements in the article as well as the methodology on which the major premise of the article is based. The statement by The BMJ that the available safety data were not disclosed to the public by the authorities or by GlaxoSmithKline is incorrect. Duringthe pandemic, safety data available to GSK and the company's analyses of those data were shared regularly with the authorities through weekly teleconferences and monthly written periodic safety update reports. Summaries of the information relating to all pandemic vaccines used in Europe were made available to the public weekly on the European Medicines Agency website.